Patent · US Active

Therapeutic dendrimer

US11118016B2 · kind B2 · utility

2Cited by

7References

18Claims

0Family size

Assignee

Starpharma Pty Ltd. · AU

Inventors

David Owen · Melbourne, AU
Brian Devlin Kelly · Melbourne, AU

Key dates

Filing date	Aug 26, 2020
Grant date	Sep 14, 2021
Priority date	—
Expiry date	Aug 26, 2040

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K9/0019
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Provided herein are dendrimers comprising: a core unit, five generations of building units which are lysine residues or analogues thereof, first terminal groups comprising a cabazitazel residue covalently attached to a diglycolyl linker group, and second terminal groups comprising a PEG group. Also provided herein are pharmaceutical compositions comprising the dendrimers, and methods and uses of the dendrimers in therapy of disorders such as cancers. Processes for making the dendrimers and intermediates are also provided.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.